Sensei Biotherapeutics, Inc.
SNSE
$7.96
$0.41395.49%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.40% | -28.46% | -34.61% | -32.99% | -32.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.39% | -15.66% | -16.91% | -22.13% | -32.34% |
| Operating Income | 17.39% | 15.66% | 16.91% | 22.13% | 32.34% |
| Income Before Tax | 9.60% | 9.05% | 11.57% | 23.43% | 34.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.60% | 9.05% | 11.57% | 23.43% | 34.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.60% | 9.05% | 11.57% | 23.43% | 34.37% |
| EBIT | 17.39% | 15.66% | 16.91% | 22.13% | 32.34% |
| EBITDA | 16.26% | 15.39% | 17.46% | 22.75% | 33.16% |
| EPS Basic | 9.68% | 4.04% | 1.04% | 9.57% | 19.87% |
| Normalized Basic EPS | 14.59% | 8.34% | 6.13% | 7.79% | 18.35% |
| EPS Diluted | 9.68% | 4.04% | 1.04% | 9.57% | 19.87% |
| Normalized Diluted EPS | 14.59% | 8.34% | 6.13% | 7.79% | 18.35% |
| Average Basic Shares Outstanding | 0.07% | -5.14% | -10.20% | -14.75% | -18.06% |
| Average Diluted Shares Outstanding | 0.07% | -5.14% | -10.20% | -14.75% | -18.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |